Canadian sanitizer firm receives NDC
This article was originally published in The Tan Sheet
Executive SummaryBritish Columbia-based Alda Pharmaceuticals receives a National Drug Code from FDA, allowing the firm to sell OTC monograph products, including its T36 antimicrobial products, in the U.S. "This is the first step in fulfilling our strategy of securing foreign sales for current products while we continue to pursue the testing and registration of the T36 therapeutics," the firm says April 7. Alda touts T36 technology as having distinct advantages over typical alcohol hand sanitizers because it kills a "wider range" of infectious organisms and lasts for hours on skin to provide continuous protection, according to the firm
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.